Rhumbline Advisers Oramed Pharmaceuticals Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$2.12 - $4.47 $3,879 - $8,180	1,830 New	1,830 $6,000
Q2 2022 Aug 11, 2022	SELL	$3.72 - $9.0 $126,651 - $306,414	-34,046 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$8.19 - $13.89 $78,714 - $133,496	9,611 Added 39.33%	34,046 $294,000
Q4 2021 Feb 10, 2022	BUY	$12.98 - $29.75 $28,711 - $65,807	2,212 Added 9.95%	24,435 $349,000
Q3 2021 Nov 12, 2021	BUY	$12.13 - $23.82 $99,963 - $196,300	8,241 Added 58.94%	22,223 $488,000
Q2 2021 Aug 05, 2021	BUY	$8.34 - $14.59 $116,609 - $203,997	13,982 New	13,982 $187,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92.4M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.